ライフサイエンスコーパス: excluded patients

1 Excluded patients included those who had not been residents i

2 diagnosed less than 1 year before the date of enrolment and excluded patients with any other malignancies.

3 e Maastricht Cardiomyopathy Registry in the Netherlands and excluded patients with ischemic, valvular, hypertensive, and

4 erified vaccination status during the influenza seasons and excluded patients with recent hospitalization, from chronic c

5 e included patients who received mechanical ventilation and excluded patients who received a tracheostomy, had a do-not-r

6 ulation that analysed patients by randomised allocation but excluded patients found ineligible after randomisation.

7 The 1-year mortality for CMS-excluded patients was double that of CMS-included patients (1

8 The 2 clinical trials that assessed this device excluded patients thought not to be candidates for OAC.

9 t acting antiviral drugs (DAAs) for hepatitis C virus (HCV) excluded patients coinfected with human immunodeficiency viru

10 ver, studies of novel cancer therapeutics have historically excluded patients with HIV.

11 uch as a nondiagnostic initial ECG, accounting for 31.2% of excluded patients.

12 Trials often excluded patients at high risk for adverse events.

13 wever, most pivotal randomized clinical trials specifically excluded patients with (severe) renal dysfunction.

14 In comparison with the excluded patients with NMOSD who had an initial longitudinall

15 was used in 27% of the PVD trials, and 4% of the PVD trials excluded patients >65 years of age.

16 amin K antagonist oral anticoagulants (NOACs) with warfarin excluded patients with moderate/severe mitral stenosis or mec

17 We excluded patients detained under sections of the Mental Healt

18 We excluded patients if they had undergone, or were on the waiti

19 We excluded patients if they had used one of the drugs during th

20 We excluded patients if they were hepatitis B-co-infected or hep

21 We excluded patients not committed to full respiratory support.

22 We excluded patients not undergoing pPCI, transfer patients for

23 We excluded patients presenting with endocarditis.

24 We excluded patients previously treated with an agent targeting

25 We excluded patients transferred from another hospital and those

26 We excluded patients undergoing electroconversion and nursing ho

27 We excluded patients who died within the first 72 hr after trans

28 We excluded patients who had acute or recent gastrointestinal bl

29 We excluded patients who had dysglycemia at baseline and those w

30 We excluded patients who had previously received any haemorrhoid

31 We excluded patients who had received antiviral treatment in the

32 We excluded patients who needed emergency medical treatment or i

33 We excluded patients who underwent surgical adrenalectomy, had a

34 We excluded patients with a non-ICU policy or with no curative t

35 We excluded patients with a severe illness that might lead to th

36 We excluded patients with contraindications to antibiotics, pre-

37 We excluded patients with cutaneous or non-severe systemic masto

38 We excluded patients with end-stage renal disease or solid organ

39 We excluded patients with left main or ostial right coronary art

40 We excluded patients with less than 3 years' follow-up, prevalen

41 We excluded patients with morphoeic or recurrent basal-cell carc

42 We excluded patients with pre-existing risk factors for iron def

43 We excluded patients with previous cancer and followed up the re

44 We excluded patients with previous exposure to lithium or one of

45 We excluded patients with prior implantable cardioverter-defibri

46 We excluded patients with prior ocular surgery other than catara

47 For acute kidney injury analysis, we excluded patients achieving acute kidney injury criteria in t

48 able to provide verbal consent or assent were included; we excluded patients with haemodynamic instability and those who

49 To account for perioperative mortality, we excluded patients who survived less than 4 months after diagn

50 imary and secondary analyses in the per-protocol set, which excluded patients with non-completion of the primary endpoint